

In the matter of the Canadian Anti-Doping Program;

**And in the matter of an anti-doping rule violation by Donovan Burgmaier asserted by the
Canadian Centre for Ethics in Sport;**

File Outcome Summary

Summary

1. The Canadian Centre for Ethics in Sport (CCES) conducted an In-Competition sample collection session on October 30, 2021, in Edmonton, AB.
2. Mr. Donovan Burgmaier (“the Athlete”) was selected for doping control. The sample provided by the Athlete returned an adverse analytical finding for Dehydrochlormethyltestosterone (“DHCMT”), a prohibited substance.
3. Following receipt of the CCES’ Notice of Charge, asserting an Anti-Doping Rule Violation (“ADRV”) for the presence and use of DHCMT, the Athlete signed an Early Admission and Acceptance Form thereby admitting the asserted violation, waiving his right to a hearing and accepting all proposed consequences.
4. In accordance with CADP Rule 10.9.3.2, the CCES has established that the Athlete committed his prior Use violation before the Notification of the Presence and Use violation (described herein) was received. Also, the first-noticed Use violation had occurred greater than 12 months before the Presence and Use violation. Therefore, the period of Ineligibility for the Presence and Use violation shall run consecutively after the sanction for the initial Use violation has expired. The violations are to be constituted a single first violation for purposes of Rule 10.9.1.

Jurisdiction

5. The CCES is an independent not-for-profit organization incorporated under the federal laws of Canada that promotes ethical conduct in all aspects of sport in Canada. The CCES also maintains and carries out the CADP, including providing anti-doping services to national sport organizations and their members.
6. As Canada’s national anti-doping organization, the CCES is in compliance with the World Anti-Doping Code (Code) and its mandatory International Standards. The CCES has implemented the Code and its mandatory International Standards through the CADP, the domestic rules which govern this proceeding. The purpose of the Code and of the CADP is to protect the rights of athletes to fair competition.
7. The Athlete is a member of the U SPORTS and participates in the sport of football. According to Part C, Rule 1.3 of the CADP, the CADP provisions apply to all members of, and participants in the activities of, sport organizations adopting it. The CADP was adopted by the U SPORTS on January 27, 2021. Therefore, as a member of U SPORTS and/or as a participant in U SPORTS sport activities, the Athlete is subject to the Rules of the CADP.

Doping Control

8. On October 30, 2021, the CCES conducted an In-Competition doping control session in Edmonton, AB. Testing was conducted on U SPORTS athletes as part of the CCES' domestic test distribution plan, all pursuant to the CADP.
9. The Athlete was notified for doping control and, together with the Doping Control Officer (DCO) from the CCES, completed the sample collection process. The Athlete's sample code number was 4519146.
10. On November 2, 2021, the Athlete's sample was received by the World Anti-Doping Agency (WADA) accredited laboratory, the INRS-Institut Armand-Frappier (INRS), in Laval, QC.

Results Management

11. The adverse analytical finding was received from the INRS on November 19, 2021. The Certificate of Analysis indicated the presence of DHCMT.
12. DHCMT is classified as a prohibited substance on the 2021 WADA Prohibited List.
13. On November 25, 2021, the CCES commenced an initial review and Notification into the Athlete's adverse analytical finding.
14. On April 19, 2022, the CCES formally issued a Notice of Charge asserting a violation against the Athlete for the Presence and Use of a prohibited substance.
15. In accordance with CADP Rule 10.2.1, the standard sanction for an ADRV involving the Presence and Use of a prohibited substance, is a four (4) year period of ineligibility. The CCES proposed the standard four (4) year sanction within its Notice of Charge of April 19, 2022.

Confirmation of Violation and Sanction

16. In accordance with CADP Rule 10.8.1, which was specifically referenced within the Notice of Charge, the CCES informed the Athlete on April 19, 2022, that should the Athlete exercise his option to sign the Early Admission and Acceptance Form, the Athlete will receive a one (1) year reduction in the four (4) year period of ineligibility asserted by the CCES.
17. On May 9, 2022, the Athlete signed and submitted the Early Admission and Acceptance Form. Accordingly, effective May 9, 2022, an additional ADRV has been confirmed against the Athlete for the Presence of the identified prohibited substance. In accordance with CADP Rules 10.2.1 and 10.8.1, the sanction for this violation is a three (3) year period of ineligibility. Additionally, in accordance with CADP Rule 10.9.3.2, the Athlete's three (3) year period of ineligibility for this additional violation will run consecutively following the completion of the three (3) year period of ineligibility that resulted from his Use violation, which is currently set to end on January 25, 2025.
18. The CCES now considers this case closed.

Dated at Ottawa, Ontario this 30th day of May 2022.



Jeremy Luke
Senior Director, Sport Integrity
CCES